Lysine deacetylase inhibition prevents diabetes by chromatin-independent immunoregulation and β-cell protection

Type 1 diabetes is due to destruction of pancreatic β-cells. Lysine deacetylase inhibitors (KDACi) protect β-cells from inflammatory destruction in vitro and are promising immunomodulators. Here we demonstrate that the clinically well-tolerated KDACi vorinostat and givinostat revert diabetes in the...

詳細記述

保存先:
書誌詳細
主要な著者: Christensen, Dan Ploug, Gysemans, Conny, Lundh, Morten, Dahllöf, Mattias Salling, Noesgaard, Daniel, Schmidt, Søren Fisker, Mandrup, Susanne, Birkbak, Nikolai, Workman, Christopher T., Piemonti, Lorenzo, Blaabjerg, Lykke, Monzani, Valmen, Fossati, Gianluca, Mascagni, Paolo, Paraskevas, Steven, Aikin, Reid A., Billestrup, Nils, Grunnet, Lars Groth, Dinarello, Charles A., Mathieu, Chantal, Mandrup-Poulsen, Thomas
フォーマット: Artigo
言語:Inglês
出版事項: National Academy of Sciences 2014
主題:
Biological Sciences
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3903225/
https://ncbi.nlm.nih.gov/pubmed/24395784
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1320850111
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料